

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

RECEIV

Art Unit:

MAR 2 1 2002

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

Filed: 19 March 1999

Application No.: 09/646,399

SCHERMAN et al.

Title: Vectors for Transferring Nucleic Acids, Compositions Containing Them and

Their Uses

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents Washington, D.C. 20231

Sir:

 \boxtimes

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) (a) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

(b)	This Inform	ation Disclosure Statement is filed after the period set forth in 37 C.F.R.
	1.97(b), but	is believed to be filed before the mailing date of a final action under §1.113
	or a notice of	of allowance under §1.311, whichever occurs first.
	(1) The ur	ndersigned attorney certifies that each item of information contained in this
	Inform	nation Disclosure Statement was cited in a communication from a foreign
	patent	office in a counterpart foreign application not more than three months prior
	to the	filing of this statement;
	(2) The ur	ndersigned attorney certifies that no item of information contained in this
	Inform	nation Disclosure Statement was cited in a communication from a foreign
	patent	office in a counterpart foreign application or, to the knowledge of the
	unders	signed attorney after making reasonable inquiry, was known to any
	indivi	dual designated in §1.56(c) more than three months prior to the filing of this
	statem	ent; or
	(3) This Is	nformation Disclosure Statement is accompanied by a transmittal letter in
	which	payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
	author	ized.
		Respectfully submitted,
		10000001011 OUULIIVOO

Karen I. Krupen, Reg. No. 34,647 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-4658 (908) 231-2626 Telefax Aventis Docket No. ST98008A US

/011 6	6)							
MAR 1 4 2002	<u>[]</u>							_
Er. et	er the Paperwo	ign (+) inside this t				ark Office: U.S. DEPAF	PTO/SB/08A (10-96) 10/31/99. OMB 0651-0031 RTMENT OF COMMERCE valid OMB control number.	+
	<i>(</i>	e for form 1449A/F	то		C	omplete if Knowi	7	
					Application Number	09/646,399	RECH	// // r
	INFO	PRMATIO	N DI	SCLOSURE	Filing Date	03-19-1999		IVEL
	STA	TEMENT	BY /	APPLICANT	First Named Inventor	SCHERMAN		
					Group Art Unit		MAR 2	2002
		(use as many si	heets a	s necessary)	Examiner Name		TEOLO	
	Shoot	1	Of	2	Attorney Docket Number	LISSTOROOR	IEUH CENTFR	1600/200

				U.S. PATENT DOCI	JMENTS	
Examiner Initials*	Cite	U.S. Pater	t Document	Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, Lines, Where Relevant
	No.1	Number	Kind Code ² (if known)		Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
				•		
				<u> </u>		

				FORE	IGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Office	Foreign Patent Doci	ument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Le
		wo	PCT/FR96/00274			08-29-1996		
		wo	PCT/US92/03999			11-26-1992		
		wo	PCT/US95/05224			11-23-1995		
		<u> </u>	<u> </u>					
								_
		} -			*****			+
								l

Examiner	Date	
Signature	Considered	i

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please whe a plus sign (+) inside this box ->

PTO/SB/08B (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known

Substitute for form 1449B/PTO INFORMATION DISCLOSURE **Application Number** 09/646,399 Filing Date STATEMENT BY APPLICANT 03-19-1999 First Named Inventor SCHERMAN Group Art Unit (use as many sheets as necessary) **Examiner Name** Sheet 2 of Attorney Docket Number USST98008

	Т	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_						
Examiner Initials*	Cite No. ¹	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),							
		COLLAS Philippe et al., Rapid Targeting of Plasmid DNA to Zabrafish Embryo Nuclei by the Nuclear Localization Signal of SV40 T Antigen, Molecular Marine Biology and Biotechnology, (1997), 6(1), 48-58	1						
		SANDOR Zoltan et al., Triple Helix Directed Psoralen Adducts Induce a Low Frequency of Recombination in an SV40 Shuttle Vector, Biochimica et Biophysica Acta, (1995), Volume 1263, 235-240							
		SEBESTYEN Magdolna G. et al., DNA Vector Chemistry: The CovALENT Attachment of Signal Peptides to Plasmid DNA, Nature Biotechnology, January 1998, Volume 16, 80-85							
	1								
	_		_						
	\downarrow								
			_						
			_						
	_								
			1						
miner ature			J						

Signature Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.